To call 2020 a “unique year” for life sciences companies would be an understatement. The COVID-19 pandemic transformed the industry, creating immense opportunities for institutions and investors to drive healthcare through innovation.
Peter Meath, Co-Head of Healthcare and Life Sciences for Commercial Banking, notes that investment in life sciences reached record-high levels across almost every category and subsector—despite unprecedented business challenges. Here are a few of the highlights:
Image: https://www.jpmorgan.com
{iframe}https://www.jpmorgan.com/commercial-banking/insights/life-sciences-startup-outlook?workspace_id=47353&suggested_content_id=5299&social_network=linkedin{/iframe}